Supplemental Data from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402070.v1

2023-01-01

Abstract:Supplemental materials and methods and legends for all supplemental figures.

What problem does this paper attempt to address?

Supplemental Figure S4 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402076.v1

2023-01-01

Abstract:Potent antitumor activity of CCDC134 in vivo.
Supplemental Figure S3 from Cytokine-like Molecule CCDC134 Contributes to CD8<sup>+</sup> T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402079

2023-01-01

Abstract:Identification of established CCDC134 transgenic mice.
Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells Against Solid Tumors

Wenqun Zhong,Zhang Xiao,Zhiyuan Qin,Jingbo Yang,Yi Wen,Ziyan Yu,Yumei Li,Neil C. Sheppard,Serge Y. Fuchs,Xiaowei Xu,Meenhard Herlyn,Carl H. June,Ellen Puré,Wei Guo

DOI: https://doi.org/10.1158/0008-5472.23952936.v1

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Supplemental Figure S5 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402073

2023-01-01

Abstract:Involvement of CD4+ T cells in the induction of antitumor activity by CCDC134.
Supplemental Figure S1 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402085

2023-01-01

Abstract:Homo sapiens and Mus musculus CCDC134 are highly similar.
Cytokine-Like Molecule Ccdc134 Contributes to Cd8(+) T-Cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.can-13-3132

IF: 11.2

2014-01-01

Cancer Research

Abstract:AbstractCCDC134 is a poorly characterized secreted protein that may act as an immune cytokine. Here, we show that CCDC134 is differentially expressed on resting and activated immune cells and that it promotes CD8+ T-cell activation, proliferation, and cytotoxicity by augmenting expression of the T-cell effector molecules IFNγ, TNFα, granzyme B, and perforin. CCDC134 facilitated infiltration of CD8+ T cells with enhanced cytolytic activity into tumors, demonstrating strong antitumor effects in a CD8+ T-cell–dependent manner. Mechanistically, in CD8+ T cells, exposure to CCDC134 promoted cell proliferation through the JAK3–STAT5 pathway, a classic feature of many cytokines of the common γ-chain (γc) cytokine receptor family. Overall, our results provide evidence that CCDC134 may serve as a member of the γc cytokine family and illustrate its potent antitumor effects by augmenting CD8+ T-cell–mediated immunity. Cancer Res; 74(20); 5734–45. ©2014 AACR.
Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Zhiliang Ma,Wen Li,Shinichi Yoshiya,Yong Xu,Masaki Hara,Yosif El‐Darawish,Tzvetanka Markova,Kyosuke Yamanishi,Hiromichi Yamanishi,Hideaki Tahara,Yoshimasa Tanaka,Haruki Okamura

DOI: https://doi.org/10.1158/1078-0432.22459815.v1

2023-01-01

Abstract:Cytotoxic activity exhibited by PECs from pre-implanted mice receiving immune checkpoint blockade and/or IL-18
Supplementary Data from the Mechanism of Anti–PD-L1 Antibody Efficacy Against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 As a Cytolytic Effector

Wenjuan Dong,Xiaojin Wu,Shoubao Ma,Yufeng Wang,Ansel P. Nalin,Zheng Zhu,Jianying Zhang,Don M. Benson,Kai He,Michael A. Caligiuri,Jianhua Yu

DOI: https://doi.org/10.1158/2159-8290.22532669.v1

2023-01-01

Abstract:Supplementary figures and figure legends as well as supplementary methods and materials
Supplementary Figure Legends 1-4 from Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Huafeng Wei,Hao Wang,Bing Lu,Bohua Li,Sheng Hou,Weizhu Qian,Kexing Fan,Jianxin Dai,Jian Zhao,Yajun Guo

DOI: https://doi.org/10.1158/0008-5472.22375065.v1

2023-01-01

Abstract:Supplementary Figure Legends 1-4 from Cancer Immunotherapy Using In vitro Genetically Modified Targeted Dendritic Cells
Supplementary Data from XCL1/Glypican-3 Fusion Gene Immunization Generates Potent Antitumor Cellular Immunity and Enhances Anti–PD-1 Efficacy

Kun Chen,Zhiyuan Wu,Hong Zhao,Yanmei Wang,Yutong Ge,Dongmei Wang,Zhengjiang Li,Changming An,Yuying Liu,Feifei Wang,Xinyu Bi,Hongying Wang,Jianqiang Cai,Chunhong Ma,Chunfeng Qu

DOI: https://doi.org/10.1158/2326-6066.22543440

2023-01-01

Abstract:Supplementary Tables 1-2 and Supplementary Figures 1-8
Supplementary Figure 2 from Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Huafeng Wei,Hao Wang,Bing Lu,Bohua Li,Sheng Hou,Weizhu Qian,Kexing Fan,Jianxin Dai,Jian Zhao,Yajun Guo

DOI: https://doi.org/10.1158/0008-5472.22375074

2023-01-01

Abstract:Supplementary Figure 2 from Cancer Immunotherapy Using In vitro Genetically Modified Targeted Dendritic Cells
Supplementary Data from Targeted Delivery of Tumor Antigens to Activated Dendritic Cells Via CD11c Molecules Induces Potent Antitumor Immunity in Mice

Huafeng Wei,Suhui Wang,David Zhang,Sheng Hou,Weizhu Qian,Bohua Li,Haipeng Guo,Geng Kou,Jian He,Hao Wang,Yajun Guo

DOI: https://doi.org/10.1158/1078-0432.22440507

2023-01-01

Abstract:Supplementary Data from Targeted Delivery of Tumor Antigens to Activated Dendritic Cells via CD11c Molecules Induces Potent Antitumor Immunity in Mice
Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Tao Jiang,Qiqi Jin,Jiahao Wang,Fengying Wu,Jian Chen,Gongyan Chen,Yunchao Huang,Jianhua Chen,Ying Cheng,QiMing Wang,Yueyin Pan,Jianying Zhou,Jianhua Shi,Xingxiang Xu,LiZhu Lin,Wei Zhang,Yiping Zhang,Yunpeng Liu,Yong Fang,Jifeng Feng,Zhehai Wang,Sheng Hu,Jian Fang,Yongqian Shu,Jiuwei Cui,Yi Hu,Wenxiu Yao,Xingya Li,Xiaoyan Lin,Rui Wang,Yongsheng Wang,Wei Shi,Gaohua Feng,Jun Ni,Beibei Mao,Dandan Ren,Huaibo Sun,Henghui Zhang,Luonan Chen,Caicun Zhou,Shengxiang Ren

DOI: https://doi.org/10.1158/1078-0432.23791953.v1

2023-01-01

Abstract:Supplementary Materials
Contribution of CCDC134, a potential cytokine, inducing CD8+ T cell-dependent antitumor effect in cancer immunotherapy (P2086)

l xiao,wenwei shao,xiaoting gong,jing huang,xiaoyan qiu

DOI: https://doi.org/10.4049/jimmunol.190.supp.132.33

2013-01-01

Abstract:Abstract CCDC134 (coiled-coil domain containing 134) was firstly identified to be a novel classical secretory protein by our lab. Although we previously identified CCDC134 as a novel MAPK-regulator which down-regulated the Raf-1/MEK/ERK and JNK/ SAPK pathways in some cancer cell lines. However, the critical function of CCDC134 still remains unclear. In view of CCDC134 characteristic, which was widely expressed in lymphocytes, especially up-regulated expression in activated CD4+, CD8+ T lymphocytes and maturated DC, we proposed the hypothesis if CCDC134 was involved in immune response as a potential cytokine. Here, we first found that CCDC134 greatly promoted activation, proliferation and cytotoxicity of CD8+ T cells via augmenting the expression of activation molecules (CD25, CD69) and effector molecules, such as IFN-γ, TNF-α, granzyme B and perforin in vitro. Moreover, by a series of experimental evidences, we have found that CCDC134 displayed strong anti-tumor activity in a CD8+ T cells, but not CD4+ T cells, and IFN-γ-dependent manner in vivo. In addition, CCDC134 markedly promoted phosphorylation of STAT5, but not STAT1, STAT3 in CD8+ T cells and CD8+ T cells proliferation augmented by CCDC134 was dependent on STAT5. Our data collectively suggested that CCDC134, perhaps was served as a so far unidentified cytokine-like protein, which showed strong anti-tumor effects via augmenting CD8+ T cells-mediated tumor immunity.
Supplementary Figure Legends from Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer

Li Liu,Xue Bai,Jian Wang,Xiaonan Tang,Dehua Wu,Shasha Du,Xiu-Ju Du,Yao-Wei Zhang,Hai‐Liang Zhu,Yuan Fang,Zhimou Guo,Qiandong Zeng,Xuejun Guo,Zhu Li,Zhong‐Yi Dong

DOI: https://doi.org/10.1158/1078-0432.22471917.v1

2023-01-01

Abstract:Supplementary figure legends
Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer

Kankan Cao,Guodong Zhang,Moran Yang,Yiying Wang,Mengdi He,Chen Zhang,Yan Huang,Jiaqi Lu,Haiou Liu

DOI: https://doi.org/10.1158/0008-5472.23627639.v1

2023-01-01

Abstract:Materials and Methods: Supplementary Figure S1 to S14 for multiple supplementary figures
Supplementary Data from Efficient Tumor Clearance and Diversified Immunity Through Neoepitope Vaccines and Combinatorial Immunotherapy

Karin L. Lee,Stephen C. Benz,Kristin C. Hicks,Andrew Nguyen,Sofia R. Gameiro,Claudia Palena,J. Zachary Sanborn,Zhen Su,Peter Ordentlich,Lars Rohlin,John H. Lee,Shahrooz Rabizadeh,Patrick Soon‐Shiong,Kayvan Niazi,Jeffrey Schlom,Duane H. Hamilton

DOI: https://doi.org/10.1158/2326-6066.22542444

2023-01-01

Abstract:Supplementary figures and tables
Supplementary Figure S5 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Jason Bugno,Liangliang Wang,Xianbin Yu,Xuezhi Cao,Jiaai Wang,Xiaona Huang,Kaiting Yang,Andras Piffko,Katherine Chen,Stephen Y. Luo,Emile Naccasha,Yuzhu Hou,Sherry Fu,Chuan He,Yang-xin Fu,Hua L. Liang,Ralph R. Weichselbaum

DOI: https://doi.org/10.1158/1078-0432.27142129

2024-01-01

Abstract:Supplementary Figure S5. Correlation of a Human DC_Ccl22 Homolog Score and CCL22 expression among multiple TCGA cohorts
Supplementary Figure S4 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Jason Bugno,Liangliang Wang,Xianbin Yu,Xuezhi Cao,Jiaai Wang,Xiaona Huang,Kaiting Yang,Andras Piffko,Katherine Chen,Stephen Y. Luo,Emile Naccasha,Yuzhu Hou,Sherry Fu,Chuan He,Yang-xin Fu,Hua L. Liang,Ralph R. Weichselbaum

DOI: https://doi.org/10.1158/1078-0432.27142132

2024-01-01

Abstract:Supplementary Figure S4. Human expression of FOXP3 with RT and correlation with a Human DC_Ccl22 Homolog Score among TCGA cohorts

Supplemental Data from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Supplemental Figure S4 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Supplemental Figure S3 from Cytokine-like Molecule CCDC134 Contributes to CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Effector Functions in Cancer Immunotherapy

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells Against Solid Tumors

Supplemental Figure S5 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Supplemental Figure S1 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Cytokine-Like Molecule Ccdc134 Contributes to Cd8(+) T-Cell Effector Functions in Cancer Immunotherapy

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Supplementary Data from the Mechanism of Anti–PD-L1 Antibody Efficacy Against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 As a Cytolytic Effector

Supplementary Figure Legends 1-4 from Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Supplementary Data from XCL1/Glypican-3 Fusion Gene Immunization Generates Potent Antitumor Cellular Immunity and Enhances Anti–PD-1 Efficacy

Supplementary Figure 2 from Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Supplementary Data from Targeted Delivery of Tumor Antigens to Activated Dendritic Cells Via CD11c Molecules Induces Potent Antitumor Immunity in Mice

Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Contribution of CCDC134, a potential cytokine, inducing CD8+ T cell-dependent antitumor effect in cancer immunotherapy (P2086)

Supplementary Figure Legends from Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer

Supplementary Data from Efficient Tumor Clearance and Diversified Immunity Through Neoepitope Vaccines and Combinatorial Immunotherapy

Supplementary Figure S5 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplementary Figure S4 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplemental Figure S3 from Cytokine-like Molecule CCDC134 Contributes to CD8<sup>+</sup> T-cell Effector Functions in Cancer Immunotherapy